Biotricity Inc. (Biotricity) today reported that it reached a record $13 million annualized revenue run rate in April,  further extending its growth by over eight percent from the $12 million run rate it announced for March 2023.  In its Corporate Impact Report published earlier this month, Biotricity described both “better patient outcomes and substantial cost savings” for patients using its devices.

Biotricity Inc. (Biotricity) today announced it has surpassed $10 million in annual revenue run rate.  “With strong revenue growth each quarter, our scale and market reach increases every day.  I am committed to continuing to drive growth and realize our potential,” says Biotricity Founder and CEO, Dr. Waqaas Al-Siddiq.

Biotricity Inc. (Biotricity) has signed a distribution agreement with one of the Top 10 US medical device distributors to distribute its cardiac monitoring solutions, Bioflux and Biotres.  With the commercialization of its Bioflux and Biotres products, Biotricity has increased its total addressable market from $1 billion to approximately $6 billion.

Biotricity Inc. (Biotricity) today announced that its Bioheart device has been named to TIME’s list of the Best Inventions of 2022. Bioheart is the first of its kind – a continuous heart rhythm monitor using advanced technology to deliver unlimited heart data insights.

Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced the U.S. launch of Biocare Cardiac. The national roll-out follows two successful pilot programs in Oklahoma City with CardioVascular Health Clinic, a medical facility providing high-quality cardiovascular care to more than 40,000 patients, and a four-month pilot with Lexington Heart Specialists in Kentucky, a medical practice providing high-quality cardiovascular care to more than 20,000 patients.

Biotricity Inc. (Biotricity) today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke.  Bioflux®, Biotricity’s high-precision, single-unit mobile cardiac telemetry device that provides real-time monitoring and transmission of the patient’s ECG information, has captured billions of heartbeats to date, monitored in real-time by Bioflux’s built in algorithms, certified cardiac technicians and benchmarked by Artificial Intelligence (AI).